Please assess the completion status of the following clinical trial:

Trial Title: Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven non-muscle invasive bladder cancer;~* Indication to intravesical instillation of BCG according to EAU guidelines;~* Age \> 18 years;~* Willingness, to participate to the study;~* Written informed consent.~Exclusion Criteria:~* Previous or ongoing BCG or different intravesical instillations;~* Urinary tract infections (UTI) or other known pathologies of the lower urinary tract;~* Indication for a radical cystectomy;~* Severe systemic disorders, including neurological pathologies, kidney, liver or heart failure;~* Contraindications to BCG use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BCG alone (Immucist®) (Type: ACTIVE_COMPARATOR): Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
- Hyaluronic acid (Type: EXPERIMENTAL): Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).

Based on this trial design, predict the completion outcome and termination type (if applicable).